Meeting
2019 ASCO Annual Meeting
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
Presenter
Christopher Sweeney, MBBS
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Plenary Session
Session Title
Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture
Track
Special Sessions
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02446405
Citation
J Clin Oncol 37, 2019 (suppl; abstr LBA2)
DOI
10.1200/JCO.2019.37.18_suppl.LBA2
Abstract #
LBA2
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.
Speaker: Andrew J. Armstrong, MD, MS, MD, MS, MS, MD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.
Speaker: A. Oliver Sartor, MD
Videos & Slides
2021 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase III KEYNOTE-991 study.
Speaker: Christian Gratzke
Videos & Slides
2020 ASCO Virtual Scientific Program
Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset.
Speaker: Umang Swami, MD